Cargando…

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low ris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petry, Karl-Ulrich, Bollaerts, Kaatje, Bonanni, Paolo, Stanley, Margaret, Drury, Rosybel, Joura, Elmar, Kjaer, Susanne K., Meijer, Chris J. L. M., Riethmuller, Didier, Soubeyrand, Benoit, Van Damme, Pierre, Bosch, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067852/ https://www.ncbi.nlm.nih.gov/pubmed/29553886 http://dx.doi.org/10.1080/21645515.2018.1450125

Ejemplares similares

Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France
por: Riethmuller, Didier, et al.
Publicado: (2015)

Single-dose nonavalent HPV vaccine: Need of the hour
por: Pal, Manidip, et al.
Publicado: (2020)

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
por: De La Fuente, Jesús, et al.
Publicado: (2019)

Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review
por: Mariani, Luciano, et al.
Publicado: (2015)

Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies
por: Godi, Anna, et al.
Publicado: (2019)

Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations
por: Bosco, Liana, et al.
Publicado: (2021)

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
por: Patel, Cyra, et al.
Publicado: (2018)

Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain
por: Perez, S., et al.
Publicado: (2017)

Age-Related Changes in the Fraction of Cervical Intraepithelial Neoplasia Grade 3 Related to HPV Genotypes Included in the Nonavalent Vaccine
por: Giannella, Luca, et al.
Publicado: (2019)

Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England()
por: Bollaerts, Kaatje, et al.
Publicado: (2019)

Nonavalent human papillomavirus vaccination as a treatment for warts in an immunosuppressed adult
por: Ferguson, Sara B., et al.
Publicado: (2017)

Correction to: Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain
por: Perez, S., et al.
Publicado: (2018)

Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily
por: Capra, Giuseppina, et al.
Publicado: (2017)

Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
por: Toh, Zheng Quan, et al.
Publicado: (2019)

Childhood erythrodermic lichen planus pemphigoides after nonavalent human papillomavirus vaccination
por: Pizzatti, Laura, et al.
Publicado: (2020)

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study
por: Gilca, Vladimir, et al.
Publicado: (2018)

Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses( )
por: Arroyo Mühr, Laila Sara, et al.
Publicado: (2022)

Taking stock and looking ahead: Behavioural science lessons for implementing the nonavalent human papillomavirus vaccine
por: Forster, Alice S., et al.
Publicado: (2016)

Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee
por: Taumberger, Nadja, et al.
Publicado: (2022)

Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease
por: Ghelardi, Alessandro, et al.
Publicado: (2021)

Nonavalent Human Papillomavirus Vaccination as a Treatment for Skin Warts in Immunosuppressed Adults: A Case Series
por: BOSSART, Simon, et al.
Publicado: (2020)

Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis
por: Choi, Horace C. W., et al.
Publicado: (2018)

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
por: Arlegui, Hugo, et al.
Publicado: (2020)

Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
por: Ferris, Daron G., et al.
Publicado: (2020)

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
por: Boiron, L., et al.
Publicado: (2016)

Benefit–Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project
por: Bollaerts, Kaatje, et al.
Publicado: (2018)

Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines
por: Arlegui, Hugo, et al.
Publicado: (2020)

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
por: Petersen, Lone K., et al.
Publicado: (2017)

Human Papillomavirus Infections in Cervical Samples From HIV-Positive Women: Evaluation of the Presence of the Nonavalent HPV Genotypes and Genetic Diversity
por: Sias, Catia, et al.
Publicado: (2020)

Vaccine-Preventable Disease Incidence Based on Clinically, Radiologically, and Etiologically Confirmed Outcomes: Systematic Literature Review and Re-analysis of Pneumococcal Conjugate Vaccine Efficacy Trials
por: Bollaerts, Kaatje, et al.
Publicado: (2021)

Bias due to differential and non-differential disease- and exposure misclassification in studies of vaccine effectiveness
por: De Smedt, Tom, et al.
Publicado: (2018)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

HPV prevalence in vulvar cancer in Austria
por: Pils, Sophie, et al.
Publicado: (2017)

The use of urine in the follow-up of HPV vaccine trials
por: Vorsters, Alex, et al.
Publicado: (2015)

HPV and cervical cancer: screening or vaccination?
por: Bosch, F X, et al.
Publicado: (2008)

HPV - immune response to infection and vaccination
por: Stanley, Margaret
Publicado: (2010)

Improved benchmark-multiplier method to estimate the prevalence of ever-injecting drug use in Belgium, 2000–10
por: Bollaerts, Kaatje, et al.
Publicado: (2013)

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
por: Joura, Elmar A, et al.
Publicado: (2012)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
por: Maldonado, Ivette, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ntjiu5eqnpc49cedj6rqi7a226